Industry experts expect tighter scrutiny of policy wording and exchange exposure, while warning that limited specialist capacity could constrain loss absorption.
KDB said no plans, including another attempt to sell the life insurer, had been finalised and that it would review the entire sale process and explore various alternatives.
Changes in business mix, pricing and risk selection improved underwriting, but capital-market volatility left the insurer with a net loss for the first nine months of 2026.
The US$1bn quota equals about 2% of the insurance industry's existing US$42bn QDII allowance, making the scheme a testing ground rather than an immediate growth driver, the agency said.
The parliamentary committee has also urged Bank Negara Malaysia to extend protection against health insurance premium increases exceeding 10% to all policyholders.
The insurer's combined ratio fell to 96.8% in Q3 2026 due to greater contribution from higher-margin business and continued optimisation of its core business lines.